Forecasting Three-Month Outcomes in a Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR) and Atomoxetine (Strattera) in School-Aged Children With ADHD
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: Compare observed and forecasted efficacy of mixed amphetamine salts extended release (MAS-XR; Adderall) with atomoxetine (Strattera) in ADHD children. Method: The authors analyze data from a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study of children ages 6 to 12 with ADHD combined or hyperactive/impulsive type. Primary efficacy measures are attention and deportment scores on the SKAMP behavioral rating scale, and secondary efficacy measures are academic performance scores from the PERMP test. Results: MAS-XR elicits greater improvements than atomoxetine in each domain within 3 weeks of treatment, including attention, number of math problems attempted and correct, and overall clinical functioning. Treatment differences in each outcome measure at subsequent weeks are projected from generalized estimating equations to become greater with the duration of extension of the treatment regimen. Conclusion: This study suggests that relative advantages of MAS-XR seen in the first 3 weeks are likely to be maintained in subsequent weeks. (J. of Att. Dis. 2007; 11(1) 74-82)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“…study was based on a placebocontrolled study of atomoxetine that demonstrated statistically significant separation from placebo on the primary outcome measure after only 7 days of atomoxetine treatment (0.5 to 1.0 mg/kg/d), with minimal further improvement after 2 weeks (Michelson et al., 2002).”
BackgroundInfluentialWolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 2×
“…addition, atomoxetine hydrochloride recently became the first oncedaily nonstimulant medication approved for the treatment of ADHD and has proven its efficacy in reducing attentional problems and hyperactivity (Kelsey et al., 2004), especially among those who cannot tolerate stimulant medications.”
BackgroundGREENHILL, L. L., HALPERIN, J. M., & ABIKOFF, H. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00011 · Cited by 268
Greenhill, L. L., Findling, R. L., Swanson, J. M., & MPH MR ADHD Study Group (2002) · PEDIATRICS · doi:10.1542/peds.109.3.e39 · Cited by 185
Biederman, J., Lopez, F. A., Boellner, S. W., & Chandler, M. C. (2002) · Pediatrics · doi:10.1542/peds.110.2.258 · Cited by 180
Swanson, J. (2003) · CNS Drugs · doi:10.2165/00023210-200317020-00004 · Cited by 162
Hack, S., & Chow, B. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750143465 · Cited by 120 · cited 1×
“However, the traditional formulations of these medications, although effective, require multiple daily dosing, which may contribute to suboptimal compliance and less satisfaction with treatment (Claxton, Cramer, & Pierce, 2001; Hack & Chow, 2001; Swanson, 2003).”
BackgroundBiederman, J., Quinn, D., Weiss, M., Markabi, S., Weidenman, M., Edson, K., Karlsson, G., Pohlmann, H., & Wigal, S. (2003) · Pediatric Drugs · doi:10.2165/00148581-200305120-00006 · Cited by 95 · cited 1×
“…these appear to provide the same level of effectiveness as traditional multiple-daily dosing regimens while minimizing or alleviating these associated difficulties (Biederman, Lopez, Boellner, & Chandler, 2002; Biederman et al., 2003; Greenhill, Findling, & Swanson, 2002; Wolraich et al., 2001).”
BackgroundSelf-citation
Cited by
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
Self-citationComparing the efficacy of medications for ADHD using meta-analysis.
(2006) · PubMed Central · Cited by 230
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“The comparison of MAS XR with atomoxetine is extremely limited because data were only collected up to 3 weeks after starting treatment [83] and these data were only extrapolated to 3 months [84].”
BackgroundMethod
Metadata
- Authors
- Faraone, S. V., Wigal, S. B., & Hodgkins, P.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 11
- Issue
- 1
- Pages
- 74-82
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2045053874
- Cited by
- 32
- References
- 9
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Forecasting Three-Month Outcomes in a Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR) and Atomoxetine (Strattera) in School-Aged Children With ADHD. https://app.cochat.ai/papers/10.1177/1087054706292196
- The paper
- Faraone, S. V., Wigal, S. B., & Hodgkins, P. (2007). Forecasting Three-Month Outcomes in a Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR) and Atomoxetine (Strattera) in School-Aged Children With ADHD. Journal of Attention Disorders. https://doi.org/10.1177/1087054706292196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.